尿激酶型纤溶酶原激活物和纤溶酶原激活物抑制剂1可预测预后良好的乳腺癌患者是否发生转移。
Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
作者信息
De Cremoux Patricia, Grandin Laure, Diéras Véronique, Savignoni Alexia, Degeorges Armelle, Salmon Rémy, Bollet Marc A, Reyal Fabien, Sigal-Zafrani Brigitte, Vincent-Salomon Anne, Sastre-Garau Xavier, Magdelénat Henri, Mignot Laurent, Fourquet Alain
机构信息
Département de Biologie des Tumeurs, Institut Curie, 26 rue d'Ulm, 75231 Paris Cedex, France.
出版信息
Anticancer Res. 2009 May;29(5):1475-82.
UNLABELLED
This retrospective analysis was designed to confirm the predictive role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type I (PAI-1) in the outcome of early stage, node-negative breast cancer patients.
PATIENTS AND METHODS
Node-negative patients having not received adjuvant chemotherapy, and for whom frozen samples were available, were selected.
RESULTS
Among the 169 patients included, 56.8% presented with uPA >3 ng/mg of proteins and/or PAI-1 >14 ng/mg of proteins. The median follow-up was 73 months. Significant correlations were found between uPA and disease-free survival (p [univariate]=0.003; p [multivariate]=0.01), and between uPA, PAI-1, and uPA plus PAI-1 and distant relapses (p=0.002). No significant correlation was found between uPA/PAI-1 and the risk of locoregional recurrence.
CONCLUSION
This study demonstrated that uPA and PAI-1 are useful predictors of distant metastases in a subset of early stage, node-negative breast cancer patients.
未标注
本回顾性分析旨在证实尿激酶型纤溶酶原激活物（uPA）和纤溶酶原激活物抑制剂I型（PAI - 1）在早期、淋巴结阴性乳腺癌患者预后中的预测作用。
患者与方法
选择未接受辅助化疗且有冷冻样本可用的淋巴结阴性患者。
结果
在纳入的169例患者中，56.8%的患者uPA>3 ng/mg蛋白和/或PAI - 1>14 ng/mg蛋白。中位随访时间为73个月。发现uPA与无病生存期之间存在显著相关性（单因素p = 0.003；多因素p = 0.01），uPA、PAI - 1以及uPA加PAI - 1与远处复发之间存在显著相关性（p = 0.002）。未发现uPA/PAI - 1与局部区域复发风险之间存在显著相关性。
结论
本研究表明，uPA和PAI - 1是一部分早期、淋巴结阴性乳腺癌患者远处转移的有用预测指标。
Zotero 插件